Background Xolair ® (omalizumab) has been approved in Canada since 2004 for the treatment of moderate to severe persistent allergic asthma in patients 12 years of age. The use of omalizumab in severe persistent allergic asthma may lead to decrease health care utilization through emergency room (ER) visits, hospitalizations, visits to health care providers, as well as, decrease the use of cortic...

This review aimed to analyze national and international literature on the safety of omalizumab in treatment moderate-to-severe bronchial asthma. Omalizumab is one longest-standing monoclonal antibodies first available option for severe allergic asthma patients aged 6 years. Several randomized controlled studies have established its efficiency safety, leading final registration more than 15 year...

After more than a decade of omalizumab being widely used in the treatment of asthma, the Brazilian National Commission for the Incorporation of Technologies stated its opposition to the incorporation of omalizumab use within the scope of the Unified Health Care System of Brazil.(1) That ruling runs contrary to expert opinion that the drug should be made available to a specific group of patients...

Omalizumab (anti-IgE ab) is a recombinant humanized monoclonal antibody (rhuMAb-E25) developed by immunizing mice with human IgE. Then, a monoclonal antibody was selected that recognizes IgE at the same site as the highaffinity receptor for IgE (FcεRI). Omalizumab is the only Mab to date that has been found to be effective and approved by both the FDA and European Medicines Agency (EMA) for the...

Buhl R, Soler M, Matz J, et al. Eur Respir J. 2002;20:73–78 Purpose of the Study. To examine the ability of omalizumab, an anti-immunoglobulin E (anti-IgE) agent, to maintain long-term disease control in patients with moderate-to-severe allergic asthma. Study Population. Four hundred eighty-three patients with moderate-to-severe allergic asthma maintained on beclomethasone diproprionate. Method...

272 Gender and Different Prevalence in Asthma Treatment With Anti-IGE (Omalizumab) Vincenzo Patella, MD, Giovanni Florio, and Carmine Oricchio, MD. Division of Clinical Immunology and Allergy, General Hospital, ASL Salerno, Agropoli (SA), Italy; Division of Clinical Immunology and Allergy, General Hospital, ASL Salerno, Salerno, Italy; Division of Immunohaematology, General Hospital, ASL Salern...

BACKGROUND Peanut allergy is a major public health problem that affects 1% of the population and has no effective therapy. OBJECTIVE To examine the safety and efficacy of oral desensitization in peanut-allergic children in combination with a brief course of anti-IgE mAb (omalizumab [Xolair]). METHODS We performed oral peanut desensitization in peanut-allergic children at high risk for devel...

INTRODUCTION The real life effectiveness, safety and the use of omalizumab for Portuguese patients with uncontrolled persistent allergic asthma are not sufficiently well known. The objective of this report was to make an evaluation, in a post-marketing, non-interventional, observational registry, of the Portuguese population included in the eXpeRience study. METHODS The methods used in this r...

INTRODUCTION Vernal keratoconjunctivis (VKC) is a severe form of pediatric ocular allergy, characterized by acute and chronic corneoconjunctival inflammation that may lead to visual sequelae. Although topical immunosuppressive drugs such as cyclosporine are usually effective, some severe forms may be refractory and require prolonged steroid therapy. Very few papers report the use of omalizumab ...

Immunology and Center for Basic and Clinical Immunology Research (CISI), University of Federico II, Naples, Naples, Italy. Background: Churg-Strauss Syndrome (CCS) is a rare systemic necrotizing small vessel vasculitis associated with bronchial asthma, peripheral blood eosinophilia and eosinophilic lung infiltration. Skin changes compatible with vasculitis are present in about 75% of patients. ...